Comparison
3 Hydroxyisobutyric Aciduria C0342737 vs 17p11 2 Microduplication Syndrome C2931246
Clinical comparison between 3 Hydroxyisobutyric Aciduria and 17p11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Hydroxyisobutyric Aciduria C0342737
A rare metabolic condition where the body cannot properly break down certain amino acids. It can cause developmental delay, intellectual disability, and metabolic problems. Management involves dietary modifications and supportive care.
17p11 2 Microduplication Syndrome C2931246
A chromosomal condition involving duplication on chromosome 17, related to Potocki-Lupski syndrome. Features often include developmental delays, learning challenges, and distinctive facial features.
6 comparison axes
Onset
3 Hydroxyisobutyric Aciduria C0342737
0-5
17p11 2 Microduplication Syndrome C2931246
0-null
Onset patterns differ
Severity
3 Hydroxyisobutyric Aciduria C0342737
severe
17p11 2 Microduplication Syndrome C2931246
moderate
Different severity levels
Chronic
3 Hydroxyisobutyric Aciduria C0342737
Chronic
17p11 2 Microduplication Syndrome C2931246
Chronic
Differing course
Communicable
3 Hydroxyisobutyric Aciduria C0342737
No
17p11 2 Microduplication Syndrome C2931246
No
Different transmission
Body System
3 Hydroxyisobutyric Aciduria C0342737
metabolic
17p11 2 Microduplication Syndrome C2931246
congenital
Same/different system
Category
3 Hydroxyisobutyric Aciduria C0342737
metabolic
17p11 2 Microduplication Syndrome C2931246
genetic
Different category
Bottom line
3-hydroxyisobutyric-aciduria-C0342737 and 17p11-2-microduplication-syndrome-C2931246 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Hydroxyisobutyric Aciduria C0342737 | 17p11 2 Microduplication Syndrome C2931246 | Discriminating power |
|---|---|---|---|
| Developmental delay | May occur with metabolic decompensation; exact pattern is not established. | Often described with learning challenges from early life. | Low |
| Metabolic illness | Source data support metabolic problems from impaired amino-acid breakdown. | Not described as a primary metabolic disorder. | High |
| Physical features | No distinctive facial pattern is established by the supplied data. | Distinctive facial features are often reported. | Moderate |
When to favor each condition
Choose 3 Hydroxyisobutyric Aciduria C0342737 when
Unexplained metabolic problems with developmental delay
The description centers on impaired amino-acid breakdown rather than a chromosomal duplication.
Moderate
Early childhood onset with severe course
Supplied axes list onset at 0-5 years and severe severity.
Moderate
Dietary management is being considered
Source management mentions dietary modification and supportive care, not a specific diet.
Low
Choose 17p11 2 Microduplication Syndrome C2931246 when
Congenital developmental delay with learning challenges
The condition is a chromosomal duplication, often related to Potocki-Lupski syndrome.
Moderate
Distinctive facial features are present
Facial features are part of the supplied description; they are not diagnostic alone.
Moderate
A moderate chronic congenital course is suspected
Axes classify it as moderate, chronic, congenital, and genetic.
Moderate
How key tests differ
| Test | 3 Hydroxyisobutyric Aciduria C0342737 | 17p11 2 Microduplication Syndrome C2931246 | Interpretation |
|---|---|---|---|
| Urine organic acid analysis | May be relevant to abnormal metabolite findings; no cutoff is established here. | Not expected to establish the chromosomal diagnosis. | An abnormal result is not itself a diagnosis and needs clinician review. |
| Chromosomal microarray | Not the defining test in the supplied description. | Can detect 17p11.2 duplication when clinically indicated. | Genetic confirmation should be interpreted by a qualified clinician. |
| Clinical metabolic assessment | Used to evaluate reported metabolic problems; exact tests are not specified. | May assess associated health needs but does not define the syndrome. | Test selection depends on presentation and should not be inferred from these data. |
Prognosis comparison
3 Hydroxyisobutyric Aciduria C0342737
- Outcome
- Described as severe and chronic; individual outcome is not established.
- Factors
- Developmental and metabolic problems may influence care needs.
17p11 2 Microduplication Syndrome C2931246
- Outcome
- Described as moderate and chronic; individual outcome is not established.
- Factors
- Developmental, learning, and congenital features may influence support needs.
Time frame: Both may begin in early life; long-term outcomes are not quantified here.
Diagnosis confirmation, associated complications, and access to supportive care matter; mortality is not stated.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurodevelopment | Developmental delay and intellectual disability may occur. Developmental delay and learning challenges are often described. Severity and specific deficits are not established by these source data. |
| Metabolic decompensation | Metabolic problems are part of the condition description. No primary metabolic complication is established here. Triggers, frequency, and laboratory thresholds are not provided. |
| Congenital or dysmorphic features | Not established in the supplied description. Distinctive facial features are often reported. Features support suspicion but do not replace genetic testing. |
Patient education highlights
- HighDifferent causes
One is a rare metabolic disorder; the other is a chromosomal duplication. Neither is described as communicable.
- HighCare planning
Metabolic care may include dietary modification and support; chromosomal care is individualized and supportive. No doses are specified.
- MediumWhen to seek care
New developmental concerns, illness, or feeding problems should be reviewed promptly by a clinician.